MAPT and Alzheimer disease: Quinolinic acid could deteriorate AD by activating NMDAR, accelerating ROS generation and promoting hyperphosphorylated tau proteins formation [52], suggesting quinolinic acid inhibition may provide additional benefits to AD treatment.